Background Convalescent plasma has been widely used to treat coronavirus disease 2019
(Covid-19) under the presumption that such plasma contains potentially therapeutic …

The specific antibodies induced by SARS-CoV-2 infection may provide protection against a
subsequent infection. However, the efficacy and duration of protection provided by naturally …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge and spread around the world, antibodies and vaccines to confer broad and potent …

Several studies have shown that neutralizing antibody levels correlate with immune
protection from COVID-19 and have estimated the relationship between neutralizing …

In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …

For over a century, transfusion of convalescent plasma from recovered individuals has been
tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS …

Understanding the immune responses elicited by SARS-CoV-2 infection is critical in terms of
protection against reinfection and, thus, for public health policy and vaccine development for …

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of
disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir …

Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global
public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to …

Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum
neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 …